Cytokinetics announces four HFSA presentations: 18 analysts rate Cytokinetics stock Buy

Published on 10/06/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue in the second quarter of 2026 fell 57.10 percent to USD 28.62 million. Cytokinetics stock costs EUR 56.06 on October 6, 2026 after EUR 55.86.

CYTK, US23282W6057, Illustration mit AI erstellt.

Cytokinetics (ISIN US23282W6057) was trading at EUR 56.06 at Lang & Schwarz on October 6, 2026 at 12:51 p.m. CEST, plus 0.36 percent versus the prior close of EUR 55.86. In a release dated October 2, 2026, Cytokinetics announced four HFSA presentations from October 9 to October 12, 2026. MarketBeat reported that 18 analysts rate the stock Buy, one rates it Hold and one rates it Sell.

Four presentations center on aficamten

The company scheduled two late-breaking clinical research presentations on October 12, 2026. Both examine aficamten in nonobstructive hypertrophic cardiomyopathy, including global efficacy and comprehensive exercise-performance measures, according to the October 2 release from Cytokinetics.

Two additional oral presentations cover right-ventricular function in obstructive hypertrophic cardiomyopathy and dosing and safety in nonobstructive disease. The release also says Cytokinetics plans to submit a supplemental application in the fourth quarter of 2026 after positive topline ACACIA-HCM results.

Revenue beat expectations in the second quarter

Makkler lists revenue of USD 28.62 million for the second quarter of 2026 against an estimate of USD 17.59 million. The same table shows earnings per share of minus USD 1.50 versus an estimated minus USD 1.63, a difference of USD 0.13 per share.

The comparison is mixed: revenue fell 57.10 percent from the year-earlier period, while the reported loss was narrower than the consensus estimate. For investors, the upcoming clinical presentations therefore provide a dated test of whether the aficamten program can extend the commercial story beyond the approved obstructive indication.

Stock remains below its yearly high

MarketBeat reported an average analyst target of USD 106.00 and a Moderate Buy consensus. That target is a separate U.S. dollar reference and is not combined with the Lang & Schwarz euro quotation.

The next scheduled earnings date is October 29, 2026, according to Makkler. The date places the HFSA presentations before the next reported quarterly update.

EUR 56.06 at Lang & Schwarz

Cytokinetics was trading at EUR 56.06 at Lang & Schwarz on October 6, 2026 at 12:51 p.m. CEST, plus 0.36 percent versus the prior close of EUR 55.86. The primary listing is on NASDAQ in U.S. dollars.